Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, appointed Weston Miller chief medical officer. Miller is an accomplished leader in cell and gene therapy drug development whose experience includes development roles at Graphite Bio, Astellas Gene Therapies, and Sangamo Therapeutics. He joins Epic as the company prepares to initiate a first-in-human study of its lead candidate, EPI-321, in early 2024. Miller brings over...